This has been proven to be interceded with CXCR4/CXCL12; hence, combinational therapy with anti-CXCR4 antagonists and TKIs may represent a powerful approach in the treatment of CML [93]. This evidence concerns the gene CXCR4 and chronic myelogenous leukemia, BCR-ABL1 positive.